Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4
暂无分享,去创建一个
Wei Li | G. Bubley | M. Sanda | Zheng Xia | S. Balk | M. Arredouani | H. Kissick | Sean J Gerrin | R. Schaefer | Joshua W. Russo | Huihui Ye | Adam G. Sowalsky
[1] F. Betsou,et al. A Critical Evaluation of the PAXgene Tissue Fixation System: Morphology, Immunohistochemistry, Molecular Biology, and Proteomics. , 2016, American journal of clinical pathology.
[2] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[3] B. Trock,et al. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for Active Surveillance , 2016, Modern Pathology.
[4] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[5] Martin A. Nowak,et al. Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.
[6] Faraz Hach,et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.
[7] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[8] Trevor J Pugh,et al. Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.
[9] Matthew N Davies,et al. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale , 2015, Current opinion in genetics & development.
[10] Andrew Menzies,et al. Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue , 2015, Nature Genetics.
[11] S. Srivastava,et al. A long noncoding RNA connects c-Myc to tumor metabolism , 2014, Proceedings of the National Academy of Sciences.
[12] M. Loda,et al. Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors , 2014, Clinical Cancer Research.
[13] J. Squire,et al. Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. , 2014, Cancer genetics.
[14] Christopher D. Brown,et al. Low-grade prostate cancer diverges early from high grade and metastatic disease , 2014, Cancer science.
[15] A. Haese*,et al. A tertiary Gleason pattern in the prostatectomy specimen and its association with adverse outcome after radical prostatectomy. , 2014, The Journal of urology.
[16] J. Hicks,et al. PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy , 2014, Modern Pathology.
[17] W. Isaacs,et al. Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.
[18] D. Watson,et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.
[19] Sarah H. Johnson,et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. , 2013, Cancer research.
[20] G. Bubley,et al. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. , 2013, Cancer Research.
[21] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[22] Stephen R. Piccolo,et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. , 2012, Genomics.
[23] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[24] B. Trock,et al. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.
[25] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..
[26] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[27] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[28] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[29] Matthew R Cooperberg,et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Kattan,et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.
[31] A. Partin,et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[33] C. Bieberich,et al. MYC and Prostate Cancer. , 2010, Genes & cancer.
[34] M. Rubin,et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.
[35] Y. Nakatani,et al. Molecular analysis of multifocal prostate cancer by comparative genomic hybridization , 2008, The Prostate.
[36] A. Regev,et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.
[37] J. Epstein,et al. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. , 2008, The Journal of urology.
[38] J. Paramio,et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. , 2008, Cancer research.
[39] M. Rubin,et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.
[40] Andrej Lupták,et al. A Genomewide Search for Ribozymes Reveals an HDV-Like Sequence in the Human CPEB3 Gene , 2006, Science.
[41] Leroy Hood,et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[42] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[43] R. Myers,et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.
[44] J. Hanley,et al. 20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.
[45] Kathryn A. O’Donnell,et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets , 2003, Genome Biology.
[46] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[47] A I Saeed,et al. TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.
[48] P. Walsh,et al. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. , 2001, The Journal of urology.
[49] D. Bostwick,et al. Allelic imbalance in the clonal evolution of prostate carcinoma , 1999, Cancer.
[50] D. Stéhelin,et al. Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains , 1998, Oncogene.
[51] L. Liotta,et al. Evidence of Independent Origin of Multiple Tumors From Patients With Prostate Cancer , 1998 .
[52] Liying Zhang,et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] 小林 将行. Molecular analysis of multifocal prostate cancer by comparative genomic hybridization , 2009 .
[54] W. Liang,et al. 9) TM4 Microarray Software Suite , 2006 .
[55] L. Liotta,et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. , 1998, Journal of the National Cancer Institute.
[56] N. Maitland,et al. Precise microdissection of human prostate cancers reveals genotypic heterogeneity. , 1998, Cancer research.